1. Clinical trials for Sanofi’s experimental Type 2 diabetes drug LixiLan, a combination of Lantus and Lyxumia, met their targets. The drug is expected to be approved in the U.S. in August and then in Europe by early 2017. Reuters’ analytics platform forecasts global sales of the combination drug to reach $1 billion in 2020. (Reuters)
2. IBM Watson Health has partnered with the American Diabetes Association to develop cognitive applications for doctors, researchers, and patients. The multi-year partnership will include analysis of clinical and research data to advance diabetes treatments. (ZDNet)
3. Dr. Reddy’s Laboratories will buy eight generic drugs from Teva Pharmaceutical Industries and Allergan for $350 million in cash. Teva is divesting the drugs in advance of its acquisition of Allergan’s generic products portfolio. (Reuters)
4. Global Blood Therapeutics said its experimental sickle-cell disease drug showed that certain disease metrics were met in a clinical trial, when compared to placebo. (WSJ)
5. Microsoft will acquire LinkedIn for $26.2 billion in cash. LinkedIn is expected to retain its “distinct brand, culture, and independence,” Microsoft said.
